Lundbeck’s reversed pipeline
A looming patent-vacuum has Danish pharmaceutical company Lundbeck mobilizing several late-phase projects meant to lift the task of the blockbuster Lexapro. But the pipeline is lacking in phase II candidates, despite a strategy to keep a full palette so the company has a wide array of options for the future.
af LEONORA BECK
Lundbeck is far along in the process of diversifying its portfolio to a greater range of products, so profit is not dependant on blockbusters such as the anti-depressant Lexapro.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
.jpg&w=384&q=75)
